MannKind Stock

MannKind EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of MannKind (MNKD) as of Aug 22, 2026 is 20.01. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 10.70 — a change of 87.08% (higher).

EV/EBIT

20.01

YoY

87.08%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of MannKind is 2026 20.01 . EV/EBIT (Enterprise Value to EBIT) of MannKind was 2025 10.70 . It decreases by 87.08% higher compared to the previous year.

The MannKind EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-18.49 USD
Jan 1, 2020
-16.18 USD
Jan 1, 2021
-12.07 USD
Jan 1, 2022
-11.92 USD
Jan 1, 2023
89.47 USD
Jan 1, 2024
10.70 USD
Jan 1, 2025
20.01 USD
Jan 1, 2026 (e)
-12.63 USD
The MannKind EV/EBIT history
YEAREV/EBITYoY
est-12.63-163.12%
20.01+87.08%
10.70-88.04%
89.47-850.68%
-11.92-1.22%
-12.07-25.43%
-16.18-12.49%
-18.49+85.26%
-9.98+34.07%
-7.44-164.49%
11.54-612.42%
-2.25-47.88%
-4.32+27.88%
-3.38+186.44%
-1.18+66.20%
-0.71-66.03%
-2.09+35.71%
-1.54+316.22%
-0.37+8.82%
-0.34-50.00%
-0.68
Access this data via the Eulerpool API

MannKind Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides MannKind's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates MannKind's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots MannKind's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if MannKind grows earnings faster than its peers.

MannKind Stock analysis

What does MannKind do? MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MannKind stock

EV/EBIT (Enterprise Value to EBIT) of MannKind is 20.01 in 2026.

EV/EBIT (Enterprise Value to EBIT) of MannKind changed from 10.70 to 20.01, representing a 87.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) MannKind since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s MannKind with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — MannKind

All Key Metrics — MannKind